Canon Inc., the parent company of Canon Medical Systems, has acquired Redlen Technologies, a developer of detectors based on cadmium zinc telluride (CZT) that can be used for photon-counting CT applications, according to a news report by Nikkei Asia.
Canon already owned 15% of Redlen, which is based in British Columbia, Canada, and is now moving to acquire full control of the firm. The deal is valued at $270 million, according to the news report.
Canon announced earlier this month that it is researching photon-counting CT through a collaboration with National Cancer Center Japan. Photon-counting CT can deliver higher resolution and lower radiation dose compared with conventional CT, according to the company.
Canon intends to marry Redlen's photon-counting technology with its own work on photon-counting CT being conducted in Japan, with CT scanners based on the technology becoming commercially available in 2025, according to Nikkei Asia. The Redlen acquisition is expected to be completed this fall.
